We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Postmarket Study Debacle Could Portend Wider Industry Warning
Merck Postmarket Study Debacle Could Portend Wider Industry Warning
April 18, 2012
An FDA warning that Merck could face fines for being months late on two postmarket study deadlines appears to be the first time the FDA has invoked new enforcement authority for postmarking requirements granted under the 2007 FDA Amendments Act (FDAAA) and may signal a new agency trend, a legal expert says.